Abiopharma

Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease

Oramed and Lifeward Announce Strategic Transaction

(70% Positive) Dentsply Sirona Inc (XRAY) Files Form 8-K

EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

(99% Neutral) Amneal Pharmaceuticals Inc. (AMRX) Reports Q1 2026 Financial Results

/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated <em>Staphylococcus aureus</em> Bacteremia